Issue-specific promoters active in CD44+CD24-/low breast cancer cells

Cancer Research

Volumn 68, Issue 14, 2008, Pages 5533-5539

  Bauerschmitz, Gerd J ^a,b,d   Ranki, Tuuli ^a,b   Kangasniemi, Lotta ^a,b   Ribacka, Camilla ^a,b   Eriksson, Minna ^a,b   Porten, Marius ^d   Herrmann, Isabell ^d   Ristimäki, Ari ^b,c   Virkkunen, Pekka ^b   Tarkkanen, Maija ^b   Hakkarainen, Tanja ^a,b   Kanerva, Anna ^a,b   Rein, Daniel ^d   Pesonen, Sari ^a,b   Hemminki, Akseli ^a,b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c Genome Scale Biology Program   (Finland)

^d HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA LACTALBUMIN; CD24 ANTIGEN; CYCLOOXYGENASE 2; E1A PROTEIN; HERMES ANTIGEN; MULTIDRUG RESISTANCE PROTEIN; ONCOLYTIC ADENOVIRUS; RETINOBLASTOMA PROTEIN; TELOMERASE; ANTINEOPLASTIC AGENT; ONCOLYTIC VIRUS;

ADENOVIRUS 5; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER STEM CELL; CASE REPORT; CELL KILLING; CHIMERA; CONTROLLED STUDY; HUMAN; HUMAN CELL; PLEURA EFFUSION; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS REPLICATION; ANIMAL; BIOSYNTHESIS; BREAST TUMOR; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METHODOLOGY; MOUSE; ONCOLYTIC VIROTHERAPY; PROMOTER REGION;

ADENOVIRUS E1A PROTEINS; ANIMALS; ANTIGENS, CD24; ANTIGENS, CD44; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PROMOTER REGIONS (GENETICS);

EID: 48649086074     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-5288     Document Type: Article

References (20)

1. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003;100:3983-8.
2. Kelly PN, Dakic A, Adams JM, Nutt SL, Strasser A. Tumor growth need not be driven by rare cancer stem cells. Science 2007;317:337.
3. Hill RP, Perris R. "Destemming" cancer stem cells. J Natl Cancer Inst 2007;99:1435-40.
4. Pardal R, Clarke MF, Morrison SJ. Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 2003;3:895-902.
5. Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med 2006;355:1253-61.
6. Saukkonen K, Hemminki A. Tissue-specific promoters for cancer gene therapy. Expert Opin Biol Ther 2004;4:683-96.
7. Li X, Zhang J, Gao H, et al. Transcriptional targeting modalities in breast cancer gene therapy using adenovirus vectors controlled by α-lactalbumin promoter. Mol Cancer Ther 2005;4:1850-9.
8. Yamamoto M, Alemany R, Adachi Y, Grizzle WE, Curiel DT. Characterization of the cyclooxygenase-2 promoter in an adenoviral vector and its application for the mitigation of toxicity in suicide gene therapy of gastrointestinal cancers. Mol Ther 2001;3:385-94.
9. Horikawa I, Cable PL, Afshari C, Barrett JC. Cloning and characterization of the promoter region of human telomerase reverse transcriptase gene. Cancer Res 1999;59:826-30.
10. Walther W, Wendt J, Stein U. Employment of the mdr1 promoter for the chemotherapy-inducible expression of therapeutic genes in cancer gene therapy. Gene Ther 1997;4:544-52.
11. Bauerschmitz GJ, Lam JT, Kanerva A, et al. Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. Cancer Res 2002;62:1266-70.
12. Bauerschmitz GJ, Guse K, Kanerva A, et al. Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells. Mol Ther 2006;14:164-74.
13. Kanerva A, Mikheeva GV, Krasnykh V, et al. Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin Cancer Res 2002;8:275-80.
14. Kanerva A, Zinn KR, Chaudhuri TR, et al. Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Mol Ther 2003;8:449-58.
15. Tanner M, Kapanen AI, Junttila T, et al. Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. Mol Cancer Ther 2004;3:1585-92.
16. Nettelbeck DM, Rivera AA, Balague C, Alemany R, Curiel DT. Novel oncolytic adenoviruses targeted to melanoma: specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/ promoter. Cancer Res 2002;62:4663-70.
17. Uil TG, Seki T, Dmitriev I, et al. Generation of an adenoviral vector containing an addition of a heterologous ligand to the serotype 3 fiber knob. Cancer Gene Ther 2003;10:121-4.
18. Eriksson M, Guse K, Bauerschmitz G, et al. oncolytic adenoviruses kill breast cancer initiating CD44(+) CD24(-/low) cells. Mol Ther 2007;15:2088-93.
19. Kanerva A, Raki M, Hemminki A. Gene therapy of gynecological diseases. Expert Opin Biol Ther 2007;7:1347-61.
20. Raki M, Kanerva A, Ristimaki A, et al. Combination of gemcitabine and Ad5/3-Δ24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer. Gene Ther 2005;12:1198-205.